During the corresponding time, Adc Therapeutics Sa recorded a revenue increase by 2.17 % year on year, sequentially revenue fell by -7.69 %. While revenue at the Adc Therapeutics Sa's corporate clients
Adc Therapeutics Sa's Comment on Sales, Marketing and Customers
The company focuses on therapeutic markets involving antibody drug conjugate (ADC) and non-ADC therapies, primarily targeting cancer treatment. Its product ZYNLONTA is developed for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Current third-line treatment options for DLBCL include CAR-T therapy, allogeneic stem cell transplant, polatuzumab with bendamustine and rituximab, selinexor, tafasitamab with lenalidomide, brentuximab with bendamustine and rituximab, chemotherapy with small molecules, and bispecific antibodies. If approved for second-line treatment, ZYNLONTA will compete with CAR-T therapy, autologous stem cell transplant, rituximab with chemotherapies, polatuzumab with bendamustine and rituximab, tafasitamab with lenalidomide, brentuximab with bendamustine and rituximab, and bispecific antibodies such as glofitamab, mosunetuzumab, and epcoritamab. The company is conducting the LOTIS-5 Phase 3 clinical trial to evaluate ZYNLONTA combined with rituximab versus immunochemotherapy in relapsed or refractory DLBCL patients, aiming to support expanded approval for second-line or later treatment in transplant-ineligible patients. Topline data from this trial are expected in the first half of 2026. The company faces competition from multiple firms with ADC technologies, including AbbVie, Inc., Daiichi Sankyo Company, Genmab, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Mersana Therapeutics Inc., Sanofi S.A., Roche Holding AG, Pfizer Inc., and Zymeworks, Inc.
Adc Therapeutics Sa’s Comment on Sales, Marketing and Customers
The company focuses on therapeutic markets involving antibody drug conjugate (ADC) and non-ADC therapies, primarily targeting cancer treatment. Its product ZYNLONTA is developed for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Current third-line treatment options for DLBCL include CAR-T therapy, allogeneic stem cell transplant, polatuzumab with bendamustine and rituximab, selinexor, tafasitamab with lenalidomide, brentuximab with bendamustine and rituximab, chemotherapy with small molecules, and bispecific antibodies. If approved for second-line treatment, ZYNLONTA will compete with CAR-T therapy, autologous stem cell transplant, rituximab with chemotherapies, polatuzumab with bendamustine and rituximab, tafasitamab with lenalidomide, brentuximab with bendamustine and rituximab, and bispecific antibodies such as glofitamab, mosunetuzumab, and epcoritamab. The company is conducting the LOTIS-5 Phase 3 clinical trial to evaluate ZYNLONTA combined with rituximab versus immunochemotherapy in relapsed or refractory DLBCL patients, aiming to support expanded approval for second-line or later treatment in transplant-ineligible patients. Topline data from this trial are expected in the first half of 2026. The company faces competition from multiple firms with ADC technologies, including AbbVie, Inc., Daiichi Sankyo Company, Genmab, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Mersana Therapeutics Inc., Sanofi S.A., Roche Holding AG, Pfizer Inc., and Zymeworks, Inc.
Sources:
Adc Therapeutics Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adc Therapeutics Sa’s corporate clients.
For your research, we’ve provided 9 tables on Adc Therapeutics Sa corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
200.89 %